Hepatitis B affects more than 290 people globally and is one of the world’s most devastating infectious diseases. It is the leading cause of liver diseases and very difficult to cure. However, let anybody suffering from such worry no more. Thanks to the recently announced results from a Phase 1b/2a study on BRII-179 (VBI-2601) by Brii Biosciences and VBI Vaccines (NASDAQ: VBIV). The two-part study evaluated two dose levels of BRII-179 (VBI-2601 confirming its safety, tolerability, antiviral and immunologic activities. And neither were there any side effects reported.
The Promising Human Proof-Of-Mechanism Data Reinforce the Potential for BRII-179
BRII-179 (VBI-2601) is designed to target both B-cell and T-cell immunity. Thanks to the presence of three HBV-specific surface antigens. The results of restoration of the HBV-specific antibody and T cell demonstrated by the study are promising, according to VBI Chief Medical Officer Francisco Diaz-Mitoma. It is a good indicator that all systems are set to develop a solution to this persistent and highly infectious disease.
“We are encouraged by the results of this study, which … further support for continuing the clinical development of BRII-179 (VBI-2601)….” Brii Bio’s Chief Medical Officer, Li Yan, announced. It will help both patients and healthcare providers significantly curb the progression of the devastating disease. Otherwise, the victims developing significant and life-threatening complications, including liver decompensation and hepatocellular carcinoma.
The data was presented in a late-breaker e-Poster at the European Association for the Study of the Liver’s (EASL) International Liver Congress (ILC) 2021.
Brii Biosciences is Advancing Eight Therapeutic Candidates
The last time the multinational company provided a corporate update was five months ago. However, the company has bounced back with another update; the significant advancement of eight therapeutic candidates across various stages of clinical development. They are expected to offer tangible solutions to some of the health issues crippling medical systems such as postpartum depression (PPD), HIV infection, COVID-19, and hepatitis –B (HBV). Meanwhile, they have also ushered another four new investigational therapies into clinical development.